US20120115878A1 - Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof - Google Patents
Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof Download PDFInfo
- Publication number
- US20120115878A1 US20120115878A1 US13/291,187 US201113291187A US2012115878A1 US 20120115878 A1 US20120115878 A1 US 20120115878A1 US 201113291187 A US201113291187 A US 201113291187A US 2012115878 A1 US2012115878 A1 US 2012115878A1
- Authority
- US
- United States
- Prior art keywords
- compound
- formula
- salt
- pyrrolo
- cyclopentyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- PMDDQOHZLBZUSO-UHFFFAOYSA-N CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1 Chemical compound CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1 PMDDQOHZLBZUSO-UHFFFAOYSA-N 0.000 description 5
- NHANOMFABJQAAH-UHFFFAOYSA-N CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1.O=C(O)CCC(=O)O Chemical compound CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1.O=C(O)CCC(=O)O NHANOMFABJQAAH-UHFFFAOYSA-N 0.000 description 4
- ADHCEFBFOBDYEC-UHFFFAOYSA-N OCc([n](C1CCCC1)c1n2)cc1cnc2Cl Chemical compound OCc([n](C1CCCC1)c1n2)cc1cnc2Cl ADHCEFBFOBDYEC-UHFFFAOYSA-N 0.000 description 4
- RMULRXHUNOVPEI-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1 RMULRXHUNOVPEI-UHFFFAOYSA-N 0.000 description 3
- RHXHGRAEPCAFML-UHFFFAOYSA-N CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1 Chemical compound CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 3
- 0 *B([3H])F.C1CCOC1.OCC#CC1=CN=C(Cl)N=C1NC1CCCC1.OCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1 Chemical compound *B([3H])F.C1CCOC1.OCC#CC1=CN=C(Cl)N=C1NC1CCCC1.OCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1 0.000 description 2
- FKIXHADFSMOMQO-UHFFFAOYSA-N C#CCO.ClC1=NC=C(Br)C(NC2CCCC2)=N1.OCC#CC1=CN=C(Cl)N=C1NC1CCCC1 Chemical compound C#CCO.ClC1=NC=C(Br)C(NC2CCCC2)=N1.OCC#CC1=CN=C(Cl)N=C1NC1CCCC1 FKIXHADFSMOMQO-UHFFFAOYSA-N 0.000 description 1
- YAALKTQMNHAMBZ-UHFFFAOYSA-N C.C#CCO.CCC.CCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1.CCOC(C)=O.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.Cl.ClC1=NC=C(Br)C(Cl)=N1.ClC1=NC=C(Br)C(NC2CCCC2)=N1.NC1[CH+]CCC1.OCC#CC1=CN=C(Cl)N=C1NC1CCCC1 Chemical compound C.C#CCO.CCC.CCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1.CCOC(C)=O.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.Cl.ClC1=NC=C(Br)C(Cl)=N1.ClC1=NC=C(Br)C(NC2CCCC2)=N1.NC1[CH+]CCC1.OCC#CC1=CN=C(Cl)N=C1NC1CCCC1 YAALKTQMNHAMBZ-UHFFFAOYSA-N 0.000 description 1
- OWKVVCFCHQJOES-BUOJPMGNSA-N C.C.C#CCO.CCC.CCOC(C)=O.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.ClC1=NC=C(Br)C(Cl)=N1.ClC1=NC=C(Br)C(NC2CCCC2)=N1.N#CC(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.NC1[CH+]CCC1.OCC#CC1=CN=C(Cl)N=C1NC1CCCC1.OCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1.[2H]CF Chemical compound C.C.C#CCO.CCC.CCOC(C)=O.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.ClC1=NC=C(Br)C(Cl)=N1.ClC1=NC=C(Br)C(NC2CCCC2)=N1.N#CC(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.NC1[CH+]CCC1.OCC#CC1=CN=C(Cl)N=C1NC1CCCC1.OCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1.[2H]CF OWKVVCFCHQJOES-BUOJPMGNSA-N 0.000 description 1
- STFAPISWXOMLLS-UHFFFAOYSA-N C.C.C.C.C.C.CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1.O=C(O)CCC(=O)O.O=C(O)CCC(=O)O Chemical compound C.C.C.C.C.C.CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1.O=C(O)CCC(=O)O.O=C(O)CCC(=O)O STFAPISWXOMLLS-UHFFFAOYSA-N 0.000 description 1
- RESYPGFIYGZFJI-UHFFFAOYSA-N C.C.C.C.CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1 Chemical compound C.C.C.C.CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1 RESYPGFIYGZFJI-UHFFFAOYSA-N 0.000 description 1
- JXBLNSJEBKRYLG-UHFFFAOYSA-N C.C.C.CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)N=C2N1C1CCCC1 Chemical compound C.C.C.CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)N=C2N1C1CCCC1 JXBLNSJEBKRYLG-UHFFFAOYSA-N 0.000 description 1
- DDJBZEUARNAYON-UHFFFAOYSA-N C.C.C.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1.O=C(O)CCC(=O)O.O=C(O)CCC(=O)O Chemical compound C.C.C.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1.O=C(O)CCC(=O)O.O=C(O)CCC(=O)O DDJBZEUARNAYON-UHFFFAOYSA-N 0.000 description 1
- WCYQUNUHVVONCT-UHFFFAOYSA-N C.C.C1CCOC1.C1CNCCN1.CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CC(C)(C)OC(=O)N1CCN(C2=CN=C([N+](=O)[O-])C=C2)CC1.CCCCO.CO.Cl.O=BC#CO.O=[N+]([O-])C1=NC=C(Cl)C=C1.O=[N+]([O-])C1=NC=C(N2CCNCC2)C=C1 Chemical compound C.C.C1CCOC1.C1CNCCN1.CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CC(C)(C)OC(=O)N1CCN(C2=CN=C([N+](=O)[O-])C=C2)CC1.CCCCO.CO.Cl.O=BC#CO.O=[N+]([O-])C1=NC=C(Cl)C=C1.O=[N+]([O-])C1=NC=C(N2CCNCC2)C=C1 WCYQUNUHVVONCT-UHFFFAOYSA-N 0.000 description 1
- FTVOPLLZNDSLAI-UHFFFAOYSA-N C.C.C1CNCCN1.CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CC(C)(C)OCN1CCN(C2=CN=C([N+](=O)[O-])C=C2)CC1.CCCCO.CO.Cl.O.O=[N+]([O-])C1=NC=C(Cl)C=C1.O=[N+]([O-])C1=NC=C(N2CCNCC2)C=C1 Chemical compound C.C.C1CNCCN1.CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CC(C)(C)OCN1CCN(C2=CN=C([N+](=O)[O-])C=C2)CC1.CCCCO.CO.Cl.O.O=[N+]([O-])C1=NC=C(Cl)C=C1.O=[N+]([O-])C1=NC=C(N2CCNCC2)C=C1 FTVOPLLZNDSLAI-UHFFFAOYSA-N 0.000 description 1
- ZHFTWJSCWLFMSL-UHFFFAOYSA-N C.C.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1.Cl Chemical compound C.C.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1.Cl ZHFTWJSCWLFMSL-UHFFFAOYSA-N 0.000 description 1
- NLSZKWIQQAMFAD-UHFFFAOYSA-N C.C1CNCCN1.CC1=NC=C(N2CCN(C(=O)OC(C)(C)C)CC2)C=C1.C[N+](=O)C1=NC=C(N2CCNCC2)C=C1.Cl.Cl.O=[N+]([O-])C1=NC=C(Cl)C=C1.O=[N+]([O-])C1=NC=C(N2CCNCC2)C=C1 Chemical compound C.C1CNCCN1.CC1=NC=C(N2CCN(C(=O)OC(C)(C)C)CC2)C=C1.C[N+](=O)C1=NC=C(N2CCNCC2)C=C1.Cl.Cl.O=[N+]([O-])C1=NC=C(Cl)C=C1.O=[N+]([O-])C1=NC=C(N2CCNCC2)C=C1 NLSZKWIQQAMFAD-UHFFFAOYSA-N 0.000 description 1
- XJBMWSJQTJHIMJ-UHFFFAOYSA-N C.CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CC(C)(C)OC(=O)N1CCN(C2=CN=C([N+](=O)[O-])C=C2)CC1.CO Chemical compound C.CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CC(C)(C)OC(=O)N1CCN(C2=CN=C([N+](=O)[O-])C=C2)CC1.CO XJBMWSJQTJHIMJ-UHFFFAOYSA-N 0.000 description 1
- TZVGHHRYNLAWLW-UHFFFAOYSA-N C.CCC#CC1=CN=C(Cl)N=C1NC1CCCC1.CCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1.ClC1=NC=C(Br)C(Cl)=N1.ClC1=NC=C(Br)C(NC2CCCC2)=N1.ClC1=NC=C(Br)C(NC2CCCC2)=N1.NC1CCCC1.OCC#CC1=CN=C(Cl)N=C1NC1CCCC1.OCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1 Chemical compound C.CCC#CC1=CN=C(Cl)N=C1NC1CCCC1.CCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1.ClC1=NC=C(Br)C(Cl)=N1.ClC1=NC=C(Br)C(NC2CCCC2)=N1.ClC1=NC=C(Br)C(NC2CCCC2)=N1.NC1CCCC1.OCC#CC1=CN=C(Cl)N=C1NC1CCCC1.OCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1 TZVGHHRYNLAWLW-UHFFFAOYSA-N 0.000 description 1
- AUJWHUBUOUNASX-UHFFFAOYSA-N C.CCC.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.N#C[Na].OCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1 Chemical compound C.CCC.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.N#C[Na].OCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1 AUJWHUBUOUNASX-UHFFFAOYSA-N 0.000 description 1
- JRSMMXZRAUGTFC-UHFFFAOYSA-M C1CCOC1.CC(C)(C)OC(=O)N1CCN(C2=CN=C([N+](=O)[O-])C=C2)CC1.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.Cl.O=COO[K].O=[N+]([O-])C1=NC=C(N2CCNCC2)C=C1.[KH] Chemical compound C1CCOC1.CC(C)(C)OC(=O)N1CCN(C2=CN=C([N+](=O)[O-])C=C2)CC1.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.Cl.O=COO[K].O=[N+]([O-])C1=NC=C(N2CCNCC2)C=C1.[KH] JRSMMXZRAUGTFC-UHFFFAOYSA-M 0.000 description 1
- ZGYRJLMUMLZPSL-UHFFFAOYSA-N C1CNCCN1.CC(C)(C)OC(=O)N1CCN(C2=CN=C([N+](=O)[O-])C=C2)CC1.CC1=NC=C(N2CCN(C(=O)OC(C)(C)C)CC2)C=C1.C[N+](=O)C1=NC=C(N2CCN(C(=O)OC(C)(C)C)CC2)C=C1.C[N+](=O)C1=NC=C(N2CCNCC2)C=C1.Cl.Cl.O=[N+]([O-])C1=NC=C(Cl)C=C1.O=[N+]([O-])C1=NC=C(N2CCNCC2)C=C1 Chemical compound C1CNCCN1.CC(C)(C)OC(=O)N1CCN(C2=CN=C([N+](=O)[O-])C=C2)CC1.CC1=NC=C(N2CCN(C(=O)OC(C)(C)C)CC2)C=C1.C[N+](=O)C1=NC=C(N2CCN(C(=O)OC(C)(C)C)CC2)C=C1.C[N+](=O)C1=NC=C(N2CCNCC2)C=C1.Cl.Cl.O=[N+]([O-])C1=NC=C(Cl)C=C1.O=[N+]([O-])C1=NC=C(N2CCNCC2)C=C1 ZGYRJLMUMLZPSL-UHFFFAOYSA-N 0.000 description 1
- KLCOUCUJZGQJCG-UHFFFAOYSA-N C1CNCCN1.CCCCO.Cl.O=[N+]([O-])C1=NC=C(Cl)C=C1.O=[N+]([O-])C1=NC=C(N2CCNCC2)C=C1 Chemical compound C1CNCCN1.CCCCO.Cl.O=[N+]([O-])C1=NC=C(Cl)C=C1.O=[N+]([O-])C1=NC=C(N2CCNCC2)C=C1 KLCOUCUJZGQJCG-UHFFFAOYSA-N 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-N CC(=O)CCC(=O)O Chemical compound CC(=O)CCC(=O)O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 1
- JIYFGHPPACJHGF-UHFFFAOYSA-N CC(=O)CCC(=O)O.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1 Chemical compound CC(=O)CCC(=O)O.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1 JIYFGHPPACJHGF-UHFFFAOYSA-N 0.000 description 1
- REYPVAMVZTZVDA-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)N=C2N1C1CCCC1 Chemical compound CC(C)(C)OC(=O)N1CCN(C2=CN=C(N)C=C2)CC1.CN(C)C(=O)C1=CC2=CN=C(Cl)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)N=C2N1C1CCCC1 REYPVAMVZTZVDA-UHFFFAOYSA-N 0.000 description 1
- XJXXETLOTJUCAN-UHFFFAOYSA-N CC1=NC=C(N2CCN(C(=O)OC(C)(C)C)CC2)C=C1 Chemical compound CC1=NC=C(N2CCN(C(=O)OC(C)(C)C)CC2)C=C1 XJXXETLOTJUCAN-UHFFFAOYSA-N 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N CCC Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- FONDXRLUKKJFNF-UHFFFAOYSA-N CCC#CC1=CN=C(Cl)N=C1NC1CCCC1 Chemical compound CCC#CC1=CN=C(Cl)N=C1NC1CCCC1 FONDXRLUKKJFNF-UHFFFAOYSA-N 0.000 description 1
- ISLISEADHWCGJU-UHFFFAOYSA-N CCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1 Chemical compound CCC1=CC2=CN=C(Cl)N=C2N1C1CCCC1 ISLISEADHWCGJU-UHFFFAOYSA-N 0.000 description 1
- AGXGSDQNCZWDSG-UHFFFAOYSA-N CCOC(C)=O.ClC1=NC=C(Br)C(Cl)=N1.ClC1=NC=C(Br)C(NC2CCCC2)=N1.NC1[CH+]CCC1 Chemical compound CCOC(C)=O.ClC1=NC=C(Br)C(Cl)=N1.ClC1=NC=C(Br)C(NC2CCCC2)=N1.NC1[CH+]CCC1 AGXGSDQNCZWDSG-UHFFFAOYSA-N 0.000 description 1
- KXBOMRITIOTRHC-UHFFFAOYSA-N CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1 Chemical compound CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)N=C2N1C1CCCC1.CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C1CCCC1 KXBOMRITIOTRHC-UHFFFAOYSA-N 0.000 description 1
- CHGKAGOTEWCHJL-UHFFFAOYSA-N OCC#Cc(c(NC1CCCC1)n1)cnc1Cl Chemical compound OCC#Cc(c(NC1CCCC1)n1)cnc1Cl CHGKAGOTEWCHJL-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- FIG. 1 shows Dynamic Vapor Sorption (DVS) isotherm plot of Compound of Formula (II) (0-90-0% Relative Humidity (RH) Cycle).
- the succinate salt is greater than 99% in the form of non-hydrate.
- the succinate salt is greater than 97% in the form of non-hydrate.
- a nitrogen-flushed, suitably equipped 5 L 4-neck round bottom flask is charged with 250 g (1.097 mol, 140.4 mL, 1.0 eq.) of 5-bromo-2,4-dichloropyrimidine (A1h) and 1127 g, (1250 mL) of ethyl acetate. The content is stirred at 20° C. and 283.5 g (2.194 mol, 382.0 mL, 2.0 eq.) of N,N-diisopropylethylamine is added.
- a nitrogen-flushed, suitably equipped 22 L 4-neck round bottom flask is charged with 589 g (2.41 mol, 1.0 eq.) of 1-(6-nitropyridin-3-yl)piperazine hydrochloride (A2b).
- a solution of 630.5 g (2.89 mol, 1.2 eq) of di-tert-butyl dicarbonate in 10,223 g (11,500 mL) of tetrahydrofuran is prepared and charged to the flask. The resulting suspension is stirred and cooled to 8 ⁇ 3° C.
- a nitrogen-flushed, suitably equipped 5 L 4-neck round bottom flask is charged with 499 g (3.61 mol, 1.5 eq.) of potassium carbonate.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/291,187 US20120115878A1 (en) | 2010-11-10 | 2011-11-08 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
US14/307,901 US20150099760A1 (en) | 2010-11-10 | 2014-06-18 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41206410P | 2010-11-10 | 2010-11-10 | |
US13/291,187 US20120115878A1 (en) | 2010-11-10 | 2011-11-08 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/307,901 Continuation US20150099760A1 (en) | 2010-11-10 | 2014-06-18 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120115878A1 true US20120115878A1 (en) | 2012-05-10 |
Family
ID=45094234
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/291,187 Abandoned US20120115878A1 (en) | 2010-11-10 | 2011-11-08 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
US13/882,353 Active US9193732B2 (en) | 2010-11-10 | 2011-11-09 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
US14/307,901 Abandoned US20150099760A1 (en) | 2010-11-10 | 2014-06-18 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
US14/887,790 Active US9868739B2 (en) | 2010-11-10 | 2015-10-20 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/882,353 Active US9193732B2 (en) | 2010-11-10 | 2011-11-09 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
US14/307,901 Abandoned US20150099760A1 (en) | 2010-11-10 | 2014-06-18 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
US14/887,790 Active US9868739B2 (en) | 2010-11-10 | 2015-10-20 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Country Status (24)
Country | Link |
---|---|
US (4) | US20120115878A1 (ar) |
EP (2) | EP2638030B1 (ar) |
JP (4) | JP2013542257A (ar) |
KR (4) | KR20130132433A (ar) |
CN (4) | CN113956257A (ar) |
AR (2) | AR083797A1 (ar) |
AU (4) | AU2011326620A1 (ar) |
BR (2) | BR112013010167B1 (ar) |
CA (1) | CA2815839C (ar) |
CL (1) | CL2013001282A1 (ar) |
CO (1) | CO6781544A2 (ar) |
EC (1) | ECSP13012619A (ar) |
ES (1) | ES2803432T3 (ar) |
GT (1) | GT201300123A (ar) |
IL (1) | IL225580B (ar) |
JO (1) | JO3670B1 (ar) |
MA (1) | MA34653B1 (ar) |
MX (1) | MX370852B (ar) |
MY (1) | MY164274A (ar) |
PE (1) | PE20140065A1 (ar) |
RU (1) | RU2631243C2 (ar) |
SG (1) | SG189229A1 (ar) |
TW (1) | TWI549953B (ar) |
WO (1) | WO2012064805A1 (ar) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014097125A1 (en) * | 2012-12-20 | 2014-06-26 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
US8957074B2 (en) | 2010-02-19 | 2015-02-17 | Novartis Ag | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 |
WO2018039324A1 (en) | 2016-08-23 | 2018-03-01 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
US10005726B2 (en) | 2015-06-04 | 2018-06-26 | Suzhou Miracpharma Technology Co., Ltd. | Ribociclib intermediate and preparation method therefor |
US20180243304A1 (en) * | 2015-08-28 | 2018-08-30 | Novartis Ag | Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer |
WO2018170447A1 (en) | 2017-03-16 | 2018-09-20 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
CN109400612A (zh) * | 2018-12-24 | 2019-03-01 | 重庆三圣实业股份有限公司 | 一种瑞博西尼的制备方法及其产品和用途 |
CN117069663A (zh) * | 2023-08-31 | 2023-11-17 | 四川维亚本苑生物科技有限公司 | 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法 |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
UA114178C2 (uk) | 2011-07-01 | 2017-05-10 | Новартіс Аг | Комбінація, що включає інгібітор cdk4/6 і інгібітор pi3k, для лікування раку |
JP2017516855A (ja) * | 2014-05-28 | 2017-06-22 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | 特定のタンパク質キナーゼ阻害剤 |
CN105294737B (zh) * | 2014-07-26 | 2019-02-12 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
EP4183806A3 (en) | 2014-11-12 | 2023-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
CN105111215B (zh) * | 2014-12-12 | 2019-06-18 | 苏州晶云药物科技股份有限公司 | 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法 |
US10138250B2 (en) | 2014-12-12 | 2018-11-27 | Crystal Pharmatech Co., Ltd. | Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt |
EP3231805B1 (en) * | 2014-12-12 | 2020-03-04 | Crystal Pharmatech Co. Ltd. | Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt |
WO2016151501A1 (en) | 2015-03-25 | 2016-09-29 | Novartis Ag | Pharmaceutical combinations |
EP3279201B1 (en) * | 2015-04-01 | 2019-10-23 | Crystal Pharmatech Co., Ltd. | Cdk inhibitor, eutectic crystal of mek inhibitor, and preparation method therefor |
PL3283058T3 (pl) | 2015-04-16 | 2023-03-20 | Novartis Ag | Tabletka rybocyklibu |
EP3156406A1 (en) | 2015-10-14 | 2017-04-19 | ratiopharm GmbH | Crystalline forms of ribociclib free base |
IL302822A (en) | 2015-11-12 | 2023-07-01 | Seagen Inc | Compounds interacting with glycans and methods of use |
CN106749259B (zh) * | 2015-11-19 | 2019-02-01 | 华东师范大学 | 一种环戊基嘧啶并吡咯类化合物的合成方法 |
CN107266451B (zh) * | 2016-04-07 | 2021-12-31 | 上海医药工业研究院 | 瑞布昔利布中间体的制备方法 |
RU2738837C2 (ru) | 2016-05-07 | 2020-12-17 | Шанхай Фокон Фармасьютикал Ко., Лтд. | Некоторые ингибиторы протеинкиназы |
WO2018051280A1 (en) * | 2016-09-15 | 2018-03-22 | Dr. Reddy’S Laboratories Limited | Process for preparation of ribociclib, its acid addition salts |
CN106478641B (zh) * | 2016-10-09 | 2018-07-24 | 杭州科巢生物科技有限公司 | 瑞博西尼中间体的合成方法 |
EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE |
CN108314686A (zh) * | 2017-01-18 | 2018-07-24 | 西南民族大学 | 一种新颖的Ribociclib制备方法 |
KR102653141B1 (ko) | 2017-03-03 | 2024-04-01 | 씨젠 인크. | 글리칸-상호작용 화합물 및 사용 방법 |
CN108586356B (zh) * | 2017-03-16 | 2021-02-19 | 杭州科巢生物科技有限公司 | 瑞博西尼新中间体及其制备瑞博西尼的合成方法 |
CN108623599A (zh) * | 2017-03-17 | 2018-10-09 | 西南民族大学 | 一种快速合成Ribociclib方法 |
CN106928236B (zh) * | 2017-05-06 | 2019-05-31 | 山东君瑞医药科技有限公司 | 一种瑞博西尼的合成工艺 |
CN109206373B (zh) * | 2017-07-07 | 2022-02-15 | 上海医药工业研究院 | 一种帕博昔布中间体5-溴-2-氯-4-环戊基氨基嘧啶的制备工艺 |
CN111094290B (zh) * | 2017-07-27 | 2022-06-17 | 苏州晶云药物科技股份有限公司 | 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途 |
MX2020002123A (es) | 2017-08-25 | 2020-09-18 | Sicor Soc It Corticosteroidi S R L | Sales de ribociclib y formas en estado sólido de las mismas. |
CN111433375A (zh) | 2017-08-31 | 2020-07-17 | 诺华股份有限公司 | 选择针对癌症患者的治疗的方法 |
US11286259B2 (en) | 2017-09-29 | 2022-03-29 | Hangzhou Solipharma Co., Ltd. | Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof |
JP7100125B2 (ja) * | 2017-10-27 | 2022-07-12 | フレゼニウス・カビ・オンコロジー・リミテッド | リボシクリブおよびその塩の改善された調製のためのプロセス |
WO2019111160A1 (en) * | 2017-12-04 | 2019-06-13 | Sun Pharmaceutical Industries Limited | Crystalline forms of ribociclib succinate |
WO2019123364A1 (en) * | 2017-12-22 | 2019-06-27 | Shilpa Medicare Limited | Novel polymorphs of ribociclib mono succinate |
WO2019130068A1 (en) * | 2017-12-29 | 2019-07-04 | Dr. Reddy’S Laboratories Limited | Crystalline forms of ribociclib succinate |
CN107936029B (zh) * | 2018-01-08 | 2020-06-30 | 南京奇可药业有限公司 | 一种合成瑞博西尼的方法 |
CN110016024B (zh) * | 2018-01-09 | 2021-09-03 | 南京药石科技股份有限公司 | 一种合成cdk4/6双重抑制剂的关键中间体及其制备方法和应用 |
US11414421B2 (en) | 2018-01-20 | 2022-08-16 | Natco Pharma Ltd | Process for the preparation of ribociclib succinate and its novel crystalline forms thereof |
WO2019150181A1 (en) * | 2018-02-05 | 2019-08-08 | Biophore India Pharmaceuticals Pvt Ltd | Improved process for the preparation of 7-cyclopentyl-n, n-dimethyl-2-(5-(piperazin-1-yl) pyridin-2-ylaminuteso)-7h-pyrrolo[2,3-d] pyrimidine-6-carboxamide succinate (ribociclib succinate) and its crystalline forms thereof |
WO2019166987A1 (en) * | 2018-02-28 | 2019-09-06 | Sun Pharmaceutical Industries Limited | A process for the preparation of ribociclib and its intermediates |
WO2019167068A1 (en) | 2018-03-01 | 2019-09-06 | Cipla Limited | Novel polymorphs of ribociclib succinate |
US10723739B2 (en) | 2018-05-14 | 2020-07-28 | Apotex Inc. | Processes for the preparation of Ribociclib and intermediates thereof |
TWI675662B (zh) | 2018-05-17 | 2019-11-01 | 中化合成生技股份有限公司 | 瑞博西尼琥珀酸鹽(Ribociclib succinate salt)晶型B、C及D與其衍生物,以及其等之製造方法與藥物組合物 |
CA3048036A1 (en) | 2018-07-02 | 2020-01-02 | Apotex Inc | Novel crystalline form of ribociclib succinate |
CN110156793B (zh) * | 2018-07-13 | 2022-01-14 | 安礼特(上海)医药科技有限公司 | 瑞博西尼单琥珀酸盐新晶型及制备方法 |
WO2020084389A1 (en) | 2018-10-23 | 2020-04-30 | Lupin Limited | Ribociclib intermediate and process for preparation thereof |
CN111100128B (zh) * | 2018-10-26 | 2022-09-06 | 广安凯特制药有限公司 | 一种瑞博西尼中间产品的合成方法及其中间体化合物 |
CN113195000A (zh) | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | 抗体-药物缀合物和激酶抑制剂的组合 |
CN113316471A (zh) * | 2019-01-23 | 2021-08-27 | 诺华股份有限公司 | 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7H-吡咯并[2,3-d]嘧啶-6-羧酸二甲基酰胺的琥珀酸盐的新的结晶形式 |
WO2020225827A1 (en) * | 2019-05-08 | 2020-11-12 | Mylan Laboratories Limited | Novel polymorphs of ribociclib succinate |
CN112010857B (zh) * | 2019-05-30 | 2021-11-05 | 常州制药厂有限公司 | 一种瑞博西尼单丁二酸盐的晶型 |
WO2021038590A1 (en) | 2019-08-30 | 2021-03-04 | Mylan Laboratories Limited | Novel polymorph of ribociclib succinate |
JP2023525100A (ja) | 2020-05-12 | 2023-06-14 | ノバルティス アーゲー | Craf阻害剤を含む治療的組み合わせ |
EP4313987A2 (en) | 2021-04-01 | 2024-02-07 | KRKA, d.d., Novo mesto | Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof |
CN113636973B (zh) * | 2021-09-07 | 2023-04-07 | 山东铂源药业股份有限公司 | 一种4-(6-氨基吡啶-3-基)哌嗪-1-羧酸叔丁酯的工业化制备方法 |
WO2023107525A1 (en) | 2021-12-10 | 2023-06-15 | Eli Lilly And Company | Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor |
WO2023114264A1 (en) | 2021-12-15 | 2023-06-22 | Eli Lilly And Company | Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer |
TW202329977A (zh) | 2022-01-25 | 2023-08-01 | 瑞士商諾華公司 | 瑞博西尼藥物組成物 |
WO2024049926A1 (en) | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010020675A1 (en) * | 2008-08-22 | 2010-02-25 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI992711A1 (it) | 1999-12-27 | 2001-06-27 | Novartis Ag | Composti organici |
EA012926B1 (ru) * | 2001-12-20 | 2010-02-26 | Оси Фармасьютикалз, Инк. | Пирролопиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение |
AU2004270733B2 (en) | 2003-09-11 | 2011-05-19 | Itherx Pharma, Inc. | Cytokine inhibitors |
JP4989233B2 (ja) * | 2004-02-14 | 2012-08-01 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
WO2006008545A2 (en) * | 2004-07-22 | 2006-01-26 | Astex Therapeutics Limited | Thiazole and isothiazole derivatives as protein kinase inhibitors |
WO2006091737A1 (en) * | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
KR101375337B1 (ko) | 2005-07-22 | 2014-03-18 | 퀄컴 엠이엠에스 테크놀로지스, 인크. | 지지 구조물들을 가지는 전자기계 장치들 및 그 제조방법들 |
JP2009524589A (ja) * | 2005-12-22 | 2009-07-02 | ワイス | 置換されたイソキノリン−1,3(2h,4h)−ジオン、1−チオキソ−1,4−ジヒドロ−2h−イソキノリン−3−オン誘導体、および1,4−ジヒドロ−3(2h)−イソキノロン、ならびにキナーゼインヒビターとしてのそれらの使用 |
TWI398252B (zh) * | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
-
2011
- 2011-11-08 US US13/291,187 patent/US20120115878A1/en not_active Abandoned
- 2011-11-08 AR ARP110104165A patent/AR083797A1/es active IP Right Grant
- 2011-11-09 US US13/882,353 patent/US9193732B2/en active Active
- 2011-11-09 CN CN202110832802.9A patent/CN113956257A/zh active Pending
- 2011-11-09 AU AU2011326620A patent/AU2011326620A1/en not_active Abandoned
- 2011-11-09 PE PE2013000978A patent/PE20140065A1/es not_active Application Discontinuation
- 2011-11-09 KR KR1020137011989A patent/KR20130132433A/ko active Application Filing
- 2011-11-09 TW TW100140959A patent/TWI549953B/zh active
- 2011-11-09 ES ES11791110T patent/ES2803432T3/es active Active
- 2011-11-09 SG SG2013024534A patent/SG189229A1/en unknown
- 2011-11-09 CA CA2815839A patent/CA2815839C/en active Active
- 2011-11-09 WO PCT/US2011/059890 patent/WO2012064805A1/en active Application Filing
- 2011-11-09 BR BR112013010167-9A patent/BR112013010167B1/pt active IP Right Grant
- 2011-11-09 CN CN201510746374.2A patent/CN105399743A/zh active Pending
- 2011-11-09 RU RU2013126112A patent/RU2631243C2/ru active
- 2011-11-09 EP EP11791110.7A patent/EP2638030B1/en active Active
- 2011-11-09 BR BR122021022703-9A patent/BR122021022703B1/pt active IP Right Grant
- 2011-11-09 MY MYPI2013001156A patent/MY164274A/en unknown
- 2011-11-09 JP JP2013538838A patent/JP2013542257A/ja active Pending
- 2011-11-09 MX MX2013005292A patent/MX370852B/es active IP Right Grant
- 2011-11-09 KR KR1020197023852A patent/KR20190099090A/ko not_active Application Discontinuation
- 2011-11-09 EP EP20168336.4A patent/EP3753933A1/en not_active Withdrawn
- 2011-11-09 CN CN201510746385.0A patent/CN105384741B/zh active Active
- 2011-11-09 KR KR1020187027991A patent/KR20180112079A/ko active Search and Examination
- 2011-11-09 CN CN2011800541083A patent/CN103201275A/zh not_active Withdrawn
- 2011-11-09 KR KR1020207033901A patent/KR20200136493A/ko not_active Application Discontinuation
- 2011-11-12 JO JOP/2011/0332A patent/JO3670B1/ar active
-
2013
- 2013-04-04 IL IL225580A patent/IL225580B/en active IP Right Grant
- 2013-05-07 MA MA35884A patent/MA34653B1/fr unknown
- 2013-05-08 CO CO13115442A patent/CO6781544A2/es not_active Application Discontinuation
- 2013-05-09 CL CL2013001282A patent/CL2013001282A1/es unknown
- 2013-05-10 GT GT201300123A patent/GT201300123A/es unknown
- 2013-05-10 EC ECSP13012619 patent/ECSP13012619A/es unknown
-
2014
- 2014-06-18 US US14/307,901 patent/US20150099760A1/en not_active Abandoned
-
2015
- 2015-10-20 US US14/887,790 patent/US9868739B2/en active Active
-
2016
- 2016-05-27 AU AU2016203534A patent/AU2016203534B2/en active Active
- 2016-10-14 JP JP2016202167A patent/JP6534375B2/ja active Active
- 2016-10-14 JP JP2016202168A patent/JP2017039757A/ja not_active Withdrawn
-
2017
- 2017-08-30 AU AU2017221805A patent/AU2017221805A1/en not_active Abandoned
-
2018
- 2018-09-28 JP JP2018184166A patent/JP2019038809A/ja active Pending
- 2018-12-04 AU AU2018274883A patent/AU2018274883B2/en active Active
-
2020
- 2020-01-10 AR ARP200100071A patent/AR117799A2/es unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010020675A1 (en) * | 2008-08-22 | 2010-02-25 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
Non-Patent Citations (3)
Title |
---|
Bastin et al., (Organic Process Research & Development 2000, 4, 427-435) * |
Serajuddin (Advanced Drug Delivery Reviews 59 (2007) 603-616) * |
Stahl et al. (eds., Handbook of pharmaceutical salts. Properties, selection and use (Wiley-VCH, 2008), pages 265-327) * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8957074B2 (en) | 2010-02-19 | 2015-02-17 | Novartis Ag | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 |
US9309252B2 (en) | 2010-02-19 | 2016-04-12 | Novartis Ag | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 |
WO2014097125A1 (en) * | 2012-12-20 | 2014-06-26 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
US9867825B2 (en) | 2012-12-20 | 2018-01-16 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
US10005726B2 (en) | 2015-06-04 | 2018-06-26 | Suzhou Miracpharma Technology Co., Ltd. | Ribociclib intermediate and preparation method therefor |
US20180243304A1 (en) * | 2015-08-28 | 2018-08-30 | Novartis Ag | Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer |
WO2018039324A1 (en) | 2016-08-23 | 2018-03-01 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
WO2018170447A1 (en) | 2017-03-16 | 2018-09-20 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
US11083722B2 (en) | 2017-03-16 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
EP4218820A2 (en) | 2017-03-16 | 2023-08-02 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
CN109400612A (zh) * | 2018-12-24 | 2019-03-01 | 重庆三圣实业股份有限公司 | 一种瑞博西尼的制备方法及其产品和用途 |
CN117069663A (zh) * | 2023-08-31 | 2023-11-17 | 四川维亚本苑生物科技有限公司 | 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9868739B2 (en) | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
KR20190022903A (ko) | 5-클로로-n2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-n4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태 | |
AU2019340569B2 (en) | Improved method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof | |
AU2020295509B2 (en) | CDK kinase inhibitor | |
US20230322717A1 (en) | Solid form of pyrazine substituted nicotinamide, and preparation and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |